ESPS 2 REANALYSIS
A post hoc analysis was conducted using data from the European Stroke Prevention Study 2. The objective of the reanalysis of the ESPS 2 trial was to assess the efficacy of extended-release dipyridamole plus ASA compared with ASA alone for the prevention of recurrent stroke among high-risk groups. Rates of annual strokes and vascular events were determined for the extended-release dipyridamole plus ASA group (n=1,650) and the ASA monotherapy group (n=1,649), and were stratified by risk subgroup and univariate risk factors. Stroke models from the Framingham Study and the Stroke Prognostic Instrument II were applied to subjects in the European Stroke Prevention Study 2 to categorise patients into risk groups.
